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Human immunodeficiency virus (HIV) increases susceptibility to Plasmodium falciparum infection, and this has
most clearly been demonstrated in pregnant women. Variant surface antigens on the surfaces of erythrocytes
infected with P. falciparum are major targets of protective immunity. We studied the impact of HIV infection on
pregnant women’s humoral immunity to variant surface antigens expressed by placental and pediatric isolates of
P. falciparum. By flow cytometry, sera from HIV-infected women more frequently lacked antibodies to these antigens
than sera from HIV-uninfected women. This difference was similar in magnitude for pediatric isolates (unadjusted
odds ratio [OR]  6.36; 95% confidence interval [CI]  1.14, 35.32; P < 0.05) and placental isolates (unadjusted
OR  6.47; 95% CI  0.75, 55.64; P < 0.10). We divided women into high and low responders on the basis of their
antibody levels. After adjustment for CD4 count, maternal age, and gravidity, we found that HIV-infected women
more frequently had low responses to both pediatric isolates (OR  5.34; 95% CI  1.23, 23.16; P  0.025) and
placental isolates (OR  4.14; 95% CI  1.71, 10.02; P  0.002). The relative quantity of antibodies to both pediatric
isolates (P  0.035) and placental isolates (P  0.005) was lower in HIV-infected women than in HIV-uninfected
women. HIV infection has a broad impact on variant-specific immunity, which may explain the susceptibility of
infected individuals to clinical malaria episodes.
Plasmodium falciparum infection induces the expression of
variant surface antigens (VSAs) on the red blood cell (RBC)
surface. These VSAs form a highly diverse group of antigens
and appear to be the primary targets of host immunity. Adults
in areas where malaria is endemic are usually semi-immune to
P. falciparum, with this immunity being associated with the
acquisition early in childhood of antibodies directed against
VSAs. Pregnant women (especially primigravidae) have more
frequent and higher-density episodes of malaria parasitemia
than their nonpregnant counterparts (3). This arises in part
because infected RBCs (IRBCs) can sequester in the placenta
by adhering to receptors such as chondroitin sulfate A (8), and
these IRBCs express unique, pregnancy-specific VSAs to
which primigravidae lack immunity.
Antibodies that target VSAs are associated with the protec-
tion of children from clinical episodes of malaria (6). In preg-
nant women, antibodies that inhibit P. falciparum adhesion to
chondroitin sulfate A have been associated with increased
birth weight and gestational age at delivery (7), and antibodies
to total VSAs were associated with a reduced prevalence of
maternal anemia and low birth weight (14). In a previous study,
we found that human immunodeficiency virus (HIV) infection
impairs pregnancy-associated variant-specific immunity, and
the impairment was the greatest in women with low CD4
counts and high viral loads (11). This impairment of humoral
immunity to pregnancy-specific VSAs may contribute to the
increased susceptibility of HIV-infected (HIV) pregnant
women to malaria and could explain their failure to demon-
strate gravidity-dependent acquisition of immunity (reviewed
in reference 15).
Studies indicate that P. falciparum infection increases the
HIV viral load in pregnant women and nonpregnant adults (10,
12) and that HIV infection increases the incidence of P. fal-
ciparum infections and clinical malaria (13, 17). All of these
data taken together suggest that malaria and HIV coinfection
in pregnant women is a major public health concern.
Given the importance of immunity to VSAs in protection
from clinical malaria (6) and our previous observation that
HIV impairs immunity to pregnancy-associated VSAs, we fur-
ther examined the impact of HIV infection on immunity. Using
a single panel of sera from HIV and HIV-negative (HIV)
women, we compared the prevalence and relative quantity of
antibody to VSAs expressed by isolates from the placenta and
isolates from children with symptomatic malaria to discover
whether the impairment of immunity to VSAs was restricted to
pregnancy-associated malaria or whether a more general de-
fect in immunity to VSAs existed.
MATERIALS AND METHODS
Sample selection and processing. P. falciparum isolates were obtained from
children admitted between October 2004 and April 2006 to the pediatric ward of
the Queen Elizabeth Central Hospital, Blantyre, Malawi, with severe and com-
plicated malaria and parasitemia of 3% or more on thin blood film examination.
Before treatment was begun, a sample of peripheral blood (300 to 500 l) was
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collected in lithium heparin tubes (D-51588; Sarstedt AG & Co., Nümbrecht,
Germany). The RBC pellet was washed three times in RPMI-HEPES medium
and cultured in human blood group O-positive RBCs in RPMI-HEPES medium
supplemented with 10% pooled human serum, 5.6% of 3.6 g/100 ml NaHCO3,
and 0.1% of 10 mg/ml gentamicin, as described elsewhere (11). The parasites
were cultured for at least 24 h to a parasitemia of 3 to 10% pigmented tropho-
zoites, as determined with Giemsa-stained thin blood films.
Placental isolates were extracted from freshly delivered placentas. Pieces of
placental tissue (2 cm3) were collected immediately upon delivery from consent-
ing women giving birth in the labor ward of the Queen Elizabeth Central
Hospital. These were placed in phosphate-buffered saline (PBS; pH 7.4) in 50-ml
Falcon tubes. Placental parasites were dislodged from the tissue by incubation at
room temperature for 2 h on a roller and three washes (1,500 rpm for 5 min each
time) in RPMI-HEPES, as described previously (2). Because the initial levels of
parasitemia varied quite widely, placental trophozoites were enriched to 90 to
98% trophozoites by using discontinuous 80%, 60%, and 40% Percoll gradients
(GE Healthcare, Uppsala, Sweden) (www.malaria.mr4.org). The parasitemia
was then reduced to approximately 10% with fresh group O-positive RBCs for
flow cytometry so that the parasitemias for the pediatric isolates and the placen-
tal isolates were similar. Seven placental isolates and 10 peripheral blood isolates
were used.
We randomly selected 20 maternal serum samples (10 HIV and 10 HIV, all
of which were of blood group O) from an existing study sample set (11, 12).
Women had undergone voluntary counseling before and after HIV testing and
had been informed of their HIV status.
Measurement of antibodies to VSAs by flow cytometry. P. falciparum IRBCs
from placental or pediatric isolates at 3 to 10% parasitemia of trophozoites were
washed three times in PBS containing 1% fetal calf serum (PBS–1% FCS) (11).
Cells at 0.1% hematocrit (100 l) were incubated with test sera at a 1:20 dilution
in PBS–1% FCS for 30 min in 5-ml polystyrene round-bottom tubes (Falcon
2008; Becton Dickinson, Franklin Lake, NJ). This was followed by a 30-min
incubation with rabbit anti-human immunoglobulin G (IgG; 50 l; Dako A/S,
Denmark) at a 1:100 dilution in PBS–1% FCS and a final incubation with Alexa
Fluor 488-conjugated donkey anti-rabbit IgG (heavy and light chains; Invitrogen,
Eugene, OR) at a 1:500 dilution and 10 mg/ml ethidium bromide at a 1:100
dilution (50 l) in the dark for 30 min. All incubations were performed at room
temperature. After each incubation, the cells were washed three times in
PBS–1% FCS. They were finally resuspended in 200 l PBS and analyzed with a
Becton Dickinson FACSCalibur flow cytometer with Cell Quest software. All
samples were run together with a positive control made up of a pool of hyper-
immune sera from pregnant women resident in Blantyre, Malawi, and two neg-
ative controls made up of pooled sera from adults in Melbourne, Australia, who
had never been exposed to the malaria parasite. The geometric mean fluores-
cence intensity (MFI) was calculated as a measure of IgG binding to IRBCs (11).
IRBCs were gated, and 1,000 positive cells were collected on the basis of
ethidium bromide fluorescence. Samples were determined to have antibodies if
the MFI was greater than the mean of the negative controls plus 2 standard
deviations (SDs). Serum samples giving readings greater than the reading for the
positive control were given a value of 100 units, and those giving a reading below
the mean value of the negative controls were given a value of 0. Sample readings
between the two controls were assigned relative values by using the formula (11)
[(serum sample reading  negative control reading)/(positive control reading 
negative control reading)]  100.
To further assess the relationship between HIV infection and antibody levels,
the latter were dichotomized into high and low responders by using a relative
MFI of 50 units.
Data management. All data collected were entered into Excel software (Mi-
crosoft Co.) and were analyzed with the Statistical Package for Social Scientists
(SPSS Inc., Chicago, IL), the Stata program (version 8.0; Stata Corporation,
College Station, TX), and the SAS program (version 9.1; SAS Institute, Inc.,
Cary, NC). Generalized estimating equations with an exchangeable correlation
matrix were used to generate odds ratios (ORs). These types of models allowed
us to take into account the clustering that resulted from the consideration of
multiple outcomes for each woman. We ran both unadjusted models and models
that adjusted for CD4 count, maternal age, and gravidity. Fisher’s exact tests
were used to assess bivariate relationships. The levels of antibodies to VSAs were
compared by the Mann-Whitney U test.
One of the HIV women had missing CD4 count data; because we had only
10 HIV subjects and wished to conduct a complete case analysis, we chose to
impute the median CD4 value (178/l) for this woman. None of the HIV
women had CD4 count data; for the sake of including them in the adjusted
models, we imputed a CD4 count of 500/l for each woman. In all analyses, age
was dichotomized at the median value (24.5 and 24.5 years); the CD4 count
(200/l and 200 l (4) and gravidity (one or two pregnancies and three or
more pregnancies) were also dichotomized.
Ethical approval. This study was approved by the College of Medicine Re-
search Committee, University of Malawi, Blantyre, Malawi; the Royal Mel-
bourne Hospital Clinical Research Ethics, Melbourne, Victoria, Australia; and
the University of North Carolina Institutional Review Board.
RESULTS
We used flow cytometry to measure antibodies to the VSAs
of P. falciparum isolates from 10 children and seven placentas.
HIV infection was associated with qualitatively and quantita-
tively lower levels of variant-specific immunity to both placen-
tal and pediatric isolates. The differences between the relative
quantity of the antibody response in infected and uninfected
women were statistically significant for pediatric isolates but
not for placental isolates (Table 1; Fig. 1). Several serum sam-
ples lacked antibodies to pediatric isolates but had antibodies
to placental isolates (Table 2).
We analyzed HIV infection status and the maternal antibody
response (absent or present) to IRBCs separately for pediatric
and placental isolates. The unadjusted odds of failure among
the HIV maternal sera to recognize pediatric isolates were
six times the odds of failure among the HIV maternal sera
(OR  6.36; 95% confidence interval [CI]  1.14, 35.32; P 
TABLE 1. Maternal antibody recognition of placental and pediatric isolatesa
Isolate type
First comparison Second comparison
Antibody
response
No. of results for
groupb OR (95% CI) P value Antibodyresponse
No. of results for
groupb OR (95% CI) P value
HIV HIV HIV HIV
Pediatric Absent 44 11 5.89 (0.84, 41.27) 0.074 Low 71 36 5.34 (1.23, 23.16) 0.025
Present 56 89 High 29 64
Placental Absent 6 1 5.78 (0.47, 70.63) 0.169 Low 54 31 4.14 (1.71, 10.02) 0.002
Present 64 69 High 16 39
a Antibody was defined as present (MFI values greater than the mean  2 SDs of the negative controls) or absent (MFI values less than or equal to the mean 
2 SDs of the negative controls) (first comparison) and high (MFI  50 units) or low (MFI  mean of 50 units) (second comparison). The OR and the 95% CI of the
failure of HIV sera to recognize IRBCs from both pediatric and placental isolates were computed by using generalized estimating equations to address the clustering
by study subject and adjusted for CD4 count (200/l and 200/l), maternal age (24.5 and 24.5 years), and gravidity (one or two pregnancies and three or more
pregnancies).
b Twenty serum samples, 10 from HIV women and 10 from HIV women, were tested against 10 pediatric isolates or 7 placental isolates.
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0.035). In the fully adjusted model, the relationship lost statis-
tical significance at the 0.05 level, although none of the covari-
ates were significant predictors (OR  5.89; 95% CI  0.84,
41.27; P  0.074). In the case of placental isolates, the mag-
nitudes of the associations in both the unadjusted model and
the fully adjusted models were similar to those for the pediatric
isolates, although neither reached statistical significance (P
values of 0.089 and 0.169, respectively) (Table 1).
We conducted an additional analysis to assess the relation-
ship between HIV infection status and antibody levels; we used
a relative MFI value of 50 units (the midpoint of our measure-
ment scale) to assign maternal antibody responses into high
responders (MFI  50 units) and low responders (MFI  50
units). Fifty units may more closely reflect a protective level of
antibody than the cutoff of the mean of our negative control
plus 2 SDs. The unadjusted odds for having a low antibody
response to pediatric isolates for HIV maternal sera were
four times the odds of having a low antibody response for
HIV maternal sera (OR  4.15; 95% CI  1.40, 12.31; P 
0.010). That relationship remained significant in the fully ad-
justed model (P  0.025). When the response to placental
isolates was dichotomized into low versus high, the unadjusted
odds for a low antibody response for HIV sera were four
times the odds for a low antibody response for HIV maternal
sera (OR  4.25; 95% CI  2.30, 7.85; P  0.001). That
relationship also remained significant in the fully adjusted
model (P  0.002) (Table 1).
HIV women had a median CD4 count of 178/l. Among
the HIV women, we found no statistically significant associ-
ation between the recognition of pediatric isolates and the
CD4 count, dichotomized as high or low (Fisher’s exact P 
0.840), nor did we find an association between the recognition
of placental isolates and a high or a low CD4 count (Fisher’s
FIG. 1. Box and whisker plots of relative levels of antibodies to
VSAs expressed by parasites infecting children (A) and parasites
infecting the placentas of pregnant women (B) for HIV and HIV
pregnant women. The data summarize the results for 20 serum
samples tested against 10 pediatric isolates (A) or against seven
placental isolates (B). The boxes show the 25th to the 75th percen-
tiles, the lines in the boxes show the median values, and the whis-
kers indicate the 95% range. P values were determined by the
Mann-Whitney U test.














C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 P1 P2 P3 P4 P5 P6 P7
A 16 1 1 226 0                 
B 35 6 1 156 0                 
C 25 3 1 91 0                 
D 31 4 1 237 0                 
E 24 3 1 133 0                 
F 34 4 1 178 0                 
G 26 1 1 —d 0                 
H 29 6 1 370 360                 
I 19 1 1 170 7,140                 
J 20 1 1 265 6,540                 
K 26 4 2 — 0                 
L 20 1 2 — 0                 
M 40 7 2 — 0                 
N 20 2 2 — 0                 
O 19 1 2 — 27,960                 
P 25 3 2 — 0                 
Q 19 1 2 — 0                 
R 23 1 2 — 0                 
S 18 1 2 — 0                 
T 32 8 2 — 0                 
a 1, HIV; 2, HIV.
b Mal, number of malaria parasites detected on peripheral blood film.
c , positive for recognition; , negative for recognition.
d —, CD4 count not measured.
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exact P  1.000). Among all study participants, maternal age
was not statistically significantly associated with the antibody
response to pediatric isolates (Fisher’s exact P  0.527) or
placental isolates (Fisher’s exact P  0.441).
When we evaluated the recognition of pediatric and placen-
tal isolates by HIV infection status and gravidity, differences
between primigravid/secundigravid women and multigravid
women emerged (Table 3). HIV sera from primigravid/se-
cundigravid women recognized 82% of the pediatric isolates,
which was similar to the value of 75% for the HIV sera
(Fisher’s exact P  0.460). However, among the multigravidae
there was a striking difference. One hundred percent of the
HIV sera recognized the pediatric isolates, but only 43% of
the HIV sera recognized the same isolates (Fisher’s exact P 
0.001). There were no significant differences in response to
placental isolates when the responses were stratified by gravid-
ity. Sera from HIV primigravid or secundigravid women
recognized 98% of the isolates, as did sera from 93% of the
HIV women (Fisher’s exact P  0.560). Among the multi-
gravid women, 100% of the HIV women and 90% of the
HIV women recognized the same isolates (P  0.144). Taken
together, these findings suggest that HIV pregnant women
have lower levels of immunity to VSAs and that this difference
is greater for immunity to variants expressed in pediatric ma-
laria than for immunity to placental isolates.
The association between HIV infection and the quantity of
antibodies to VSAs expressed by both the placental and the
pediatric isolates was also determined (Fig. 1). Sera from
HIV women had lower levels of antibodies to VSAs from
pediatric isolates (median, 36.03 units; interquartile range
[IQR], 17.07 to 52.83 units) than sera from HIV women
(median, 66.59 units; IQR, 38.99 to 80.31 units) (P  0.035).
Recognition of IRBCs from placenta was also lower when sera
from HIV women (median, 38.95 units; IQR, 31.57 to 48.09
units) than from HIV women (median, 58.55 units; IQR,
43.62 to 73.02 units) were used, and this difference was also
statistically significant (P  0.005).
DISCUSSION
We previously reported that HIV pregnant women have
fewer antibodies to VSAs from the parasite line CS2, which
expresses the var2csa gene, associated with placental malaria
(11). In the present study of clinical isolates, sera from HIV
women had fewer antibodies to VSAs expressed by IRBCs
from both placental and pediatric isolates than HIV women.
More than 90% of the maternal serum samples collected near
the time of delivery had detectable levels of antibodies to
placental VSAs, regardless of their parity and HIV infection
status, suggesting that antibodies to placenta-associated VSAs
result from a single or a very few episodes of malaria in both
HIV and HIV women. Such a restricted repertoire suggests
that these antibodies against placental isolates target relatively
conserved epitopes and therefore enable a sufficient antibody
response against pregnancy-associated malaria. Because the
present study used a range of clinical isolates rather than a
single laboratory-adapted isolate, we propose that it better
reflects the true extent of the effect of HIV on the levels of
antibodies to VSAs.
We had access only to isolates from children with severe
malaria. Isolates infecting young children and causing severe
disease may express VSAs different from those of isolates
causing mild disease or infecting older children (5). We do not
know whether the responses to isolates typically causing mild
malaria in children are less affected by HIV than those that we
tested here.
In previous studies, the levels of antibodies to most mero-
zoite and sporozoite antigens of P. falciparum did not differ
between pregnant women with and without HIV infection,
with the exception of antibodies to AMA-1 and the circum-
sporozoite protein (1, 11). Nonpregnant adults with AIDS but
not those with asymptomatic HIV infection (adults admitted to
hospital with trauma) lacked antibodies to the ring-infected
erythrocyte surface antigen (16). Our data, in conjunction with
the available published data, suggest that HIV-induced immu-
nosuppression exerts a significant effect on variant-specific im-
munity. In children, specific deficits in variant-specific immu-
nity have been associated with subsequent clinical disease due
to that variant (6). Our study was cross-sectional and was not
designed to correlate immune responses with malaria parasite
infection in the participants. Therefore, further studies are
required to determine whether a defect in variant-specific im-
munity has a critical role in the susceptibility of HIV persons
to malaria parasite infection and disease.
Our observation that HIV multigravidae were more likely
than primigravidae and secundigravidae to have impaired an-
tibody responses to pediatric isolates was unexpected. The
levels of immunosuppression (as measured by CD4 counts) did
not differ significantly with gravidity. It is well recognized that
the difference in parasite prevalence between HIV and HIV
women is greatest in multigravidae, but this has been attrib-
uted to the impact of HIV on the development of pregnancy-
specific immunity (15). In our previous study (11), the effect of
HIV infection on antibodies to pregnancy-associated VSAs
was greatest in the first pregnancy, perhaps because the ability
to develop new immune responses is more likely to be affected
than existing immunity. Observations that HIV infection in
nonpregnant adults increases parasite prevalence and clinical
disease and worsens the response to antimalarial therapy (9,
13, 17) may be explained by the effects of HIV infection on the
memory response to malaria; multigravidae might have greater
deficits in memory response because they have usually had
longer durations of HIV infection. By failing to recognize
pediatric isolates, HIV multigravidae may be more likely to
TABLE 3. Maternal antibody recognition of pediatric isolates based












Pediatric Primigravidae/secundigravidae Positive 75 0.460
Primigravidae/secundigravidae Negative 82
Multigravidae Positive 43 0.001
Multigravidae Negative 100
Placental Primigravidae/secundigravidae Positive 93 0.560
Primigravidae/secundigravidae Negative 98
Multigravidae Positive 90 0.144
Multigravidae Negative 100
a HIV versus HIV.
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be challenged by these isolates than HIV multigravidae.
These pediatric isolates do not sequester in the placenta; but
they could cause other complications of malaria, such as ane-
mia, and evidence suggests that HIV infection and malaria
have synergistic effects on anemia (15). Further studies are
required to determine the importance of this observation.
We did not have any data on the history of malaria exposure,
which may have differed between HIV and HIV women or
between women of different gravidities. Our sample size was
limited both by access to clinical isolates and by technical
limitations to the number of samples that we could test against
each isolate. A larger study would allow more definitive con-
clusions to be drawn.
These findings may have important implications for the pre-
vention of malaria in HIV individuals. A lack of immunity to
variants causing severe disease in children living in the same
environment may translate into the susceptibility of expectant
mothers to these parasite strains. Malaria prevention in HIV
pregnant women (and, perhaps, other HIV groups) may min-
imize the burden of malaria caused by an HIV-related lack of
variant-specific immunity.
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